LEXINGTON, Mass.--(BUSINESS WIRE)--Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced the success of the company’s recent user conference entitled, “Proteins Powering NextGen Healthcare: San Francisco.” The conference showcased Quanterix’ significant momentum and growth and brought together industry leaders from around the world to discuss how they’re currently leveraging innovative approaches and disruptive technologies to accelerate critical research today and change the way healthcare is practiced.
The revolutionary conference attracted leading researchers, healthcare practitioners, investors, patient advocacy groups and other stakeholders passionate about the growing importance of protein biomarkers, including how Simoa is delivering “game-changing” capabilities across a wide range of therapeutic areas, such as inflammation, neurology, cardiology, infectious disease and more. Kevin Hrusovsky, Quanterix Chairman and CEO, kicked off the conference establishing a progressive and broad vision for revolutionizing healthcare by equipping world leaders in medicine with disruptive tools for analyzing proteins and single molecules to enable early disease detection, prevention and precision drug development. He introduced Quanterix' newest technology Simoa 2.0 and unveiled plans for future products and applications that have the potential to transform medicine. Quanterix’ annual growth has exceeded 100 percent the past 18 months and the company is raising capital to further accelerate the vast potential for their technology. The company has received significant recognition, including several prominent industry award wins, such as the GE – NFL Head Health Challenge, and was featured in 51 distinguished scientific publications, 10 of which were in this year alone.
Joined by world leaders in medicine, seminal studies using Quanterix’ technology were presented. “We were impressed to see Simoa data measuring important blood biomarkers for concussion, Alzheimer’s disease, heart disease, cancer, immune system and inflammation in both healthy and diseased patients. These results validate the potential for asymptomatic healthcare and entirely new approaches for preventative medicine,” said Hrusovsky. “Our next generation platform paired with these industry leaders will lead to rapid and widespread application of this technology addressing critical problems impacting human health around the world.”
The speakers who shared their research at the conference were further energized by hearing the advances their peers were pioneering. "The ability of Quanterix' Simoa technology to measure protein biomarkers in the blood that indicate brain injury with an objective test represents an incredible turning point in the battle to change how brain injuries are diagnosed and managed,” said Robert Stern, Professor of Neurology, Neurosurgery, and Anatomy and Neurobiology at Boston University School of Medicine, where he is also Director of the Clinical Core of the BU Alzheimer’s Disease and CTE Center. “I was personally energized by the passion and commitment Kevin Hrusovsky articulated on how ultra-sensitive biomarker detection has the potential to transform medicine and personalize healthcare by detecting disease long before symptoms present. We can see this potential first hand especially in chronic traumatic encephalopathy (CTE) research."
"It was a privilege to be able to share the work my lab has been able to conduct using the Simoa platform with leading researchers and thought leaders at Quanterix' Proteins Powering Next Generation Healthcare Conference,” said Jennifer Van Eyk, Director Advanced Clinical Biosystems Research Institute, Cedars-Sinai Medical Center. “We have demonstrated the ability to measure Troponin-I in nearly all healthy individuals and have also now succeeded in developing a reliable assay for TGFb to study Marfan's disease, which has been challenging with other technologies."
With a broad spectrum of applications, Simoa is truly representative of a significant turning point in proteomic research. Dr. Jessica Gill, Principal Investigator, National Institute of Health shared how she was able to use Simoa to study military veterans returning from Iraq and Afghanistan for the objective measurement of brain injuries sustained with biomarkers in blood that were too minuscule for existing technologies to detect. She added that Quanterix, led by Kevin Hrusovsky and a talented team of scientists and management, is rapidly transforming the way we research devastating diseases such as traumatic brain injury and changing the way we look at healthcare of tomorrow.
Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit: www.quanterix.com.